Danaher snaps up diagnostics firm Masimo for $10bn
By Benjamin Chiou
Date: Tuesday 17 Feb 2026
(Sharecast News) - Masimo Corp shares soared as Wall Street opened on Tuesday after the specialty diagnostics provider agreed to be acquired by science and tech giant Danaher for nearly $10bn.
The board of Masimo, which specialises in pulse oximetry and other patient monitoring solutions, has unanimously approved a deal to be taken over for $180 per share in cash, representing a total consideration of $9.9bn.
That's a 38% premium to Friday's closing price of $130.15, prompting Masimo futures to surge 34.4% to $174.98 in early deals. Danaher, meanwhile, was down 3.4% at $205.29.
Under the terms of the deal, Masimo will become a standalone, autonomous business unit and brand within Danaher's diagnostics division.
"We look forward to joining Danaher and continuing our growth and momentum as the global leader in patient monitoring," said Masimo's chief executive Katie Szyman.
"Importantly, becoming part of Danaher's Diagnostics segment will strengthen our ability to scale our monitoring technologies globally and accelerate our mission of delivering Masimo innovations that empower clinicians to transform patient care."
Danaher expects Masimo to be accretive to adjusted diluted net earnings per share by 15 to 20 cents in the first full year of ownership, rising to 70 cents in the fifth year, compared with the $2.23 per share earned by Danaher in 2025.
The acquiring company also expects to realise more than $125m in annual cost synergies and more than $50m in revenue synergies by the fifth year following completion.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN